Most recent strategies targeting estrogen receptor alpha for the treatment of breast cancer
Abstract
Breast cancer is the most prominent, frequently diagnosed and leading cause of death among women. Estrogen is an agonist of estrogen receptor alpha (ER-α), expressed in mammary glands and is responsible for initiating many signalling pathways that lead to differentiation and development of breast tissue. Any mutations in these signalling pathways result in irregular growth of mammary tissue, leading to the development of tumour or cancer. All these observations attract the attention of researchers to antagonize ER-α receptor either by developing selective estrogen receptor modulators or by selective estrogen receptor degraders. Therefore, this article provides a brief overview of various factors that are responsible for provoking breast cancer in women and design strategies recently used by the various research groups across the world for antagonizing or demodulating ER-α.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Active ER signaling promotes the proliferation and survival of ER+ breast cancer cells, with oncogenesis primarily mediated through ERα, making it a key therapeutic target.
“Active ER signaling promotes the proliferation and survival of ER+ breast cancer cells, with oncogenesis primarily mediated through ERα, making it a key therapeutic target17.”
From Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha (2025) · cites this paper as [17]
Cites
Mechanisms of estrogen action.
Nilsson, S., Mäkelä, S., Treuter, E., Tujague, M., Thomsen, J., Andersson, G., Enmark, E., Pettersson, K., Warner, M., & Gustafsson, J.-Å. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.4.1535 · Cited by 2,059 · see citing works
Estrogen receptors: how do they signal and what are their targets
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Ström, A., Treuter, E., Warner, M., et al. (2007) · Physiological Reviews · doi:10.1152/physrev.00026.2006 · Cited by 1,857 · see citing works
Estrogen receptors and human disease
Deroo, B. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27987 · Cited by 1,322 · see citing works
† (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70425-4 · Cited by 1,162 · see citing works
Estrogen receptor signaling mechanisms
Fuentes, N., & Silveyra, P. (2019) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2019.01.001 · Cited by 1,019 · see citing works
Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential
Paterni, I., Granchi, C., Katzenellenbogen, J. A., & Minutolo, F. (2014) · Steroids · doi:10.1016/j.steroids.2014.06.012 · Cited by 736 · see citing works
Various types and management of breast cancer: An overview
Sharma, G., Dave, R., Sanadya, J., Sharma, P., & sharma, K. (2010) · Journal of Advanced Pharmaceutical Technology amp Research · doi:10.4103/2231-4040.72251 · Cited by 724 · see citing works
Transforming growth factor-β in cancer and metastasis
Jakowlew, S. B. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9006-2 · Cited by 519 · see citing works
Giordano, S. H., Buzdar, A. U., & Hortobágyi, G. N. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-8-200210150-00013 · Cited by 492 · see citing works
Quantum majorization and a complete set of entropic conditions for quantum thermodynamics
Gour, G., Jennings, D., Buscemi, F., Duan, R., & Marvian, I. (2018) · Nature Communications · doi:10.1038/s41467-018-06261-7 · Cited by 461 · see citing works
Patel, H., & Bihani, T. (2017) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 423 · see citing works
Pathogenesis, prevention, diagnosis and treatment of breast cancer
Shah, R. A. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.283 · Cited by 330 · see citing works
Krishnamurti, U., & Silverman, J. F. (2014) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000015 · Cited by 329 · see citing works
Risk determination and prevention of breast cancer
Howell, A., Anderson, A. S., Clarke, R. B., Duffy, S. W., Evans, D. G., García‐Closas, M., Gescher, A. J., Key, T. J., Saxton, J., & Harvie, M. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0446-2 · Cited by 327 · see citing works
Endocrinology: Adult and Pediatric
(2016) · Elsevier eBooks · doi:10.1016/c2012-1-03052-4 · Cited by 305 · see citing works
Understanding breast cancer – The long and winding road
Lukong, K. E. (2017) · BBA Clinical · doi:10.1016/j.bbacli.2017.01.001 · Cited by 238 · see citing works
Yue, W., Santen, R. J., Wang, J.-P., Li, Y., Verderame, M. F., Bocchinfuso, W. P., Korach, K. S., Devanesan, P. D., Todorović, R., Rogan, E. G., et al. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00377-7 · Cited by 238 · see citing works
Feng, X., Liang, Y.-Y., Liang, M., Zhai, W., & Lin, X. (2002) · Molecular Cell · doi:10.1016/s1097-2765(01)00430-0 · Cited by 232 · see citing works
Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function
Wang, S., Nath, N., Adlam, M. J., & Chellappan, S. (1999) · Oncogene · doi:10.1038/sj.onc.1202684 · Cited by 232 · see citing works
Progesterone Receptor Signaling Mechanisms
Grimm, S. L., Hartig, S. M., & Edwards, D. P. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.06.020 · Cited by 228 · see citing works
Estrogen and Progesterone Receptors in Breast Cancer
Yip, C. H., & Rhodes, A. (2014) · Future Oncology · doi:10.2217/fon.14.110 · Cited by 208 · see citing works
Multifaceted role of prohibitin in cell survival and apoptosis
Peng, Y., Chen, P., Ouyang, R., & Song, L. (2015) · APOPTOSIS · doi:10.1007/s10495-015-1143-z · Cited by 195 · see citing works
Bonkhoff, H. (2017) · The Prostate · doi:10.1002/pros.23446 · Cited by 189 · see citing works
Breast cancer and associated factors: a review.
Ataollahi, M. R., Sharifi, J., Paknahad, M. R., & Paknahad, A. (2015) · Europe PMC (PubMed Central) · Cited by 165 · see citing works
Breastfeeding and Breast Cancer Risk Reduction: Implications for Black Mothers
Anstey, E. H., Shoemaker, M. L., Barrera, C. M., O’Neil, M. E., Verma, A. B., & Holman, D. M. (2017) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2017.04.024 · Cited by 143 · see citing works
Tria, G. S., Abrams, T. J., Baird, J., Burks, H. E., Firestone, B., Gaither, L. A., Hamann, L. G., He, G., Kirby, C. A., Kim, S., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01682 · Cited by 134 · see citing works
Sieri, S., Krogh, V., BOLELLI, G., Abagnato, C. A., Grioni, S., Pala, V. M., Evangelista, A., Allemani, C., Micheli, A., Tagliabue, G., et al. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0808 · Cited by 123 · see citing works
Advances in Protein Chemistry and Structural Biology
(2020) · Advances in protein chemistry and structural biology · doi:10.1016/s1876-1623(20)30068-7 · Cited by 120 · see citing works
Estrogen Receptors: Role in Breast Cancer
Duffy, M. J. (2006) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360600739218 · Cited by 107 · see citing works
Analysis of estrogen receptor isoforms and variants in breast cancer cell lines
Al‐Bader, M., Ford, C. H. J., Al‐Ayadhy, B., & Francis, I. M. (2011) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2011.226 · Cited by 102 · see citing works
The treatment of cancer in Greek antiquity
Karpozilos, A., & Pavlidis, N. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.04.036 · Cited by 94 · see citing works
Sanguinetti, A., Polistena, A., Lucchini, R. G., Monacelli, M., Galasse, S., Avenia, S., Triola, R., Bugiantella, W., Cirocchi, R., Rondelli, F., et al. (2016) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2016.02.004 · Cited by 71 · see citing works
Fanning, S. W., Hodges-Gallagher, L., Myles, D. C., Sun, R., Fowler, C. E., Plant, I. N., Green, B. D., Harmon, C. L., Greene, G. L., & Kushner, P. J. (2018) · Nature Communications · doi:10.1038/s41467-018-04413-3 · Cited by 64 · see citing works
Dhawan, S., Kerru, N., Awolade, P., Singh, P., Saha, S. T., Kaur, M., Jonnalagadda, S. B., & Singh, P. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.10.006 · Cited by 63 · see citing works
New metalo-therapeutics of NSAIDs against human breast cancer cells
Banti, C. N., Papatriantafyllopoulou, C., Tasiopoulos, A. J., & Hadjikakou, S. K. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.067 · Cited by 54 · see citing works
Anatomy of the nipple and breast ducts.
Zucca‐Matthes, G., Urban, C. D. A., & Vallejo, A. (2016) · PubMed Central · doi:10.3978/j.issn.2227-684x.2015.05.10 · Cited by 48 · see citing works
Li, Y., Zhang, S., Zhang, J., Hu, Z., Yuan, X., Huang, J., Dong, C., Huang, S., & Zhou, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.058 · Cited by 47 · see citing works
O’Boyle, N. M., Barrett, I., Greene, L. M., Carr, M. J., Fayne, D., Twamley, B., Knox, A. J. S., Keely, N. O., Zisterer, D. M., & Meegan, M. J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01917 · Cited by 47 · see citing works
Ning, W., Hu, Z., Tang, C. C., Yang, L., Zhang, S., Dong, C., Huang, J., & Zhou, H. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00224 · Cited by 47 · see citing works
Chen, Y., Huang, S., Wu, B., Fang, J., Zhu, M., Sun, L. N., Zhang, L., Zhang, Y., Sun, M., Guo, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16308 · Cited by 46 · see citing works
VAV3 mediates resistance to breast cancer endocrine therapy
Aguilar, H., Urruticoechea, A., Halonen, P., Kiyotani, K., Mushiroda, T., Barril, X., Serra-Musach, J., Islam, A. B. M. M. K., Caizzi, L., Croce, L. D., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3664 · Cited by 45 · see citing works
Nagasawa, J. Y., Govek, S. P., Kahraman, M., Lai, A. G., Bonnefous, C., Douglas, K. L., Sensintaffar, J., Lu, N., Lee, K., Aparicio, A. M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00921 · Cited by 44 · see citing works
Tricyclic Indazoles—A Novel Class of Selective Estrogen Receptor Degrader Antagonists
Scott, J. S., Bailey, A., Buttar, D., Carbajo, R. J., Curwen, J., Davey, P. R. J., Davies, R. D. M., Degorce, S. L., Donald, C. S., Gangl, E. T., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01837 · Cited by 41 · see citing works
The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells
Jiang, Z., Guo, J., Shen, J., Jin, M., Xie, S., & Wang, L. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-42 · Cited by 41 · see citing works
How does the estrogen receptor work?
Gross, J. M., & Yee, D. (2002) · Breast Cancer Research · doi:10.1186/bcr424 · Cited by 40 · see citing works
Luo, G., Tang, Z., Lao, K., Li, X., You, Q., & Xiang, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.018 · Cited by 40 · see citing works
Treatment of breast cancer through the ages
Robinson, J. O. (1986) · The American Journal of Surgery · doi:10.1016/0002-9610(86)90461-7 · Cited by 36 · see citing works
Singla, R., Gupta, K. B., Upadhyay, S., Dhiman, M., & Jaitak, V. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.11.040 · Cited by 29 · see citing works
Du, Y., Song, L., Zhang, L., Ling, H., Zhang, Y., Chen, H., Qi, H., Shi, X., & Li, Q. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.050 · Cited by 29 · see citing works
Perkins, G. H., & Middleton, L. P. (2003) · BMJ · doi:10.1136/bmj.327.7409.239 · Cited by 28 · see citing works
Hendy, M. S., Ali, A. A., Ahmed, L., Hossam, R., Mostafa, A., Elmazar, M. M., Naguib, B. H., Attia, Y. M., & Ahmed, M. S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.068 · Cited by 25 · see citing works
Steroidal N-Sulfonylimidates: Synthesis and biological evaluation in breast cancer cells
Volkova, Y. A., Kozlov, A. S., Kolokolova, M. K., Uvarov, D. Y., Gorbatov, S. A., Andreeva, O. E., Scherbakov, A. M., & Zavarzin, I. V. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.048 · Cited by 24 · see citing works
Bernardino Ramazzini and women workers' health in the second half of the XVIIth century
Franco, G. (2012) · Journal of Public Health · doi:10.1093/pubmed/fds029 · Cited by 20 · see citing works
Hu, Z., Li, Y., Xie, B., Ning, W., Yuan, X., Huang, Y., Zhao, C., Huang, J., Dong, C., & Zhou, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111605 · Cited by 20 · see citing works
Palermo, A. F., Diennet, M., Ezzy, M. E., Williams, B. M., Cotnoir‐White, D., Mader, S., & Gleason, J. L. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.07.026 · Cited by 19 · see citing works
Kuznetsov, Y. V., Levina, I. S., Scherbakov, A. M., Andreeva, O. E., Fedyushkina, I. V., Dmitrenok, A. S., Shashkov, A. S., & Zavarzin, I. V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.042 · Cited by 18 · see citing works
Synthesis and characterization of hydrogen peroxide activated estrogen receptor beta ligands
Park, H., McEachon, J. D., & Pollock, J. A. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.04.003 · Cited by 14 · see citing works
Toyama, H., Shirakawa, H., Komai, M., Hashimoto, Y., & Fujii, S. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.07.038 · Cited by 12 · see citing works
Genetic Basis of Gonadal and Genital Development
Arboleda, V. A., Quigley, C. A., & Vilain, E. J. N. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00118-9 · Cited by 5 · see citing works
Clapp, R., Jacobs, M. M., & Howe, G. K. (2008) · Elsevier eBooks · doi:10.1016/b978-012373960-5.00276-8 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
A comprehensive review on thiazole based conjugates as anti-cancer agents
Rana, R., Kumar, N., Gulati, H. K., Sharma, A., Khanna, A., Pooja, P., Badhwar, R., Dhir, M., Jyoti, J., Singh, J. V., et al. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.136194 · Cited by 65 · see citing works
Self-citationElsayad, K. A., Elmasry, G. F., Mahmoud, S. T., & Awadallah, F. M. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107409 · Cited by 62 · see citing works
Breast Cancer MCF-7 Cell Spheroid Culture for Drug Discovery and Development
Chen, G., Liu, W., & Yan, B. (2022) · Journal of Cancer Therapy · doi:10.4236/jct.2022.133009 · Cited by 61 · see citing works
In Silico Drug Design of Anti-Breast Cancer Agents
Rajagopal, K., Kalusalingam, A., Bharathidasan, A. R., Sivaprakash, A., Shanmugam, K., Sundaramoorthy, M., & Byran, G. (2023) · Molecules · doi:10.3390/molecules28104175 · Cited by 29 · see citing works
Selective Estrogen Receptor Modulators (SERMs) for the treatment of ER+ breast cancer: An overview
Das, S., Kulkarni, S., Singh, Y., Kumar, P., & Thareja, S. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133853 · Cited by 25 · see citing works
Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer
Treeck, O., Haerteis, S., & Ortmann, O. (2023) · Cancers · doi:10.3390/cancers15061632 · Cited by 24 · see citing works
Jiang, S., Liu, K., Jiang, T., Li, H., Wei, X., Wan, X., Zhong, C., Gong, R., Chen, Z., Zou, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62288-7 · Cited by 23 · see citing works
“In this respect, tamoxifen resistance is developed in approximately 30-40% of patients with ERα-positive breast cancer.”
Kaur, K., Verma, H., Gangwar, P., Jangid, K., Dhiman, M., Kumar, V., & Jaitak, V. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107341 · Cited by 21 · see citing works
Kumar, N., Kaur, K., Kaur, N., Singh, E., & Bedi, P. M. S. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107042 · Cited by 19 · see citing works
Self-citationKumar, N., Kaur, K., & Bedi, P. M. S. (2023) · Computational and Theoretical Chemistry · doi:10.1016/j.comptc.2023.114262 · Cited by 18 · see citing works
Self-citationEjaz, I., Javed, M. A., Jan, M. S., Ikram, M., Sadiq, A., Ahmad, S., & Rashid, U. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128668 · Cited by 17 · see citing works
Kohandel, O., Sheikhi‐Mohammareh, S., Oroojalian, F., Memariani, T., Mague, J. T., & Shiri, A. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10290-8 · Cited by 16 · see citing works
Clinical Progress of Targeted Therapy for Breast Cancer: A Comprehensive Review
Debnath, A., & Mazumder, R. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096289260240311062343 · Cited by 11 · see citing works
Zhao, Y., Zhao, L., Wang, T., Liu, Z., Tang, S., Huang, H., Wu, L., & Sun, Y. (2024) · Integrative Cancer Therapies · doi:10.1177/15347354241233258 · Cited by 7 · see citing works
Activation of PERK/eIF2α/ATF4 signaling inhibits ERα expression in breast cancer
Wu, Y., Wang, G., Yang, R., Zhou, D., Chen, Q., Wu, Q., Chen, B., Yuan, L., Qu, N., Wang, H., et al. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101165 · Cited by 6 · see citing works
GÖMEÇ, M., Sayın, K., Özkaraca, M., & Özden, H. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133414 · Cited by 6 · see citing works
Muralidharan, S., Arockiam, A. J. V., & Shanmugam, K. (2022) · Journal of Natural Remedies · doi:10.18311/jnr/2022/28194 · Cited by 5 · see citing works
Roy, S., Saha, S., Dhar, D., Chakraborty, P., Roy, K. S., Mukherjee, C., Gupta, A., Bhattacharyya, S., Roy, A. K., Sengupta, S., et al. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00494-x · Cited by 5 · see citing works
Jabbar, Z. A., Mahdi, M. F., & Razik, B. M. A. (2023) · Al Mustansiriyah Journal of Pharmaceutical Sciences · doi:10.32947/ajps.v23i4.1096 · Cited by 5 · see citing works
Coaviche‐Yoval, A., Trujillo-Ferrara, J. G., Soriano-Ursua, M. A., Andrade‐Jorge, E., Sánchez‐Labastida, L. A., Luna, H., & Tovar‐Miranda, R. (2021) · Amino Acids · doi:10.1007/s00726-021-03108-2 · Cited by 5 · see citing works
Olayoku, F. R., Verhoog, N. J. D., & Louw, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1122031 · Cited by 5 · see citing works
Tserfas, M. O., Kuznetsov, Y. V., Knyazev, V. V., Levina, I. S., & Zavarzin, I. V. (2022) · Russian Chemical Bulletin · doi:10.1007/s11172-022-3593-0 · Cited by 3 · see citing works
Synthesis of novel isoflavene derivatives with anti-tumour activity
Falasca, V., Wenholz, D. S., Yu, T. T., & Kumar, N. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130350 · Cited by 3 · see citing works
Self-citationMa, T.-C., Ma, Y., Zhang, J., Liu, L., Sun, J. M., Guo, L., Liu, Q., & Sun, Y. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/3829434 · Cited by 3 · see citing works
Manjunath, R., Hakkimane, S. S., Shashikala, B. S., & Gaonkar, S. L. (2025) · Scientific Reports · doi:10.1038/s41598-025-09420-1 · Cited by 2 · see citing works
Manjunath, R., Padmapriya, M., Pandey, S., Nayak, R., Pai, K. S. R., & Gaonkar, S. L. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.144465 · Cited by 2 · see citing works
Heriberto, V. M. L., Mendoza-Figueroa, H. L., Jacobo-Herrera, N. J., Bakalara, N., González‐Juárez, D. E., Correa‐Basurto, J., & García-Vázquez, J. B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27010463 · Cited by 2 · see citing works
Pyridine as a potent antimicrobial agent and its recent discoveries
Kumar, N., Gulati, H. K., Khanna, A., Kaur, K., Singh, J. V., Kaur, S., Bedi, P. M. S., & Singh, B. B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91221-1.00003-8 · Cited by 1 · see citing works
Self-citationWang, Z., Gu, L., Yang, M., Zhou, Y., Pan, H., Qin, X. P., & Xiong, C. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-025-18995-y · Cited by 1 · see citing works
Serial fuzzy system algorithm for predicting biological activity of anti-breast cancer compounds
Zhao, W., Chen, D., Zheng, X., & Lu, Y. (2022) · Applied Intelligence · doi:10.1007/s10489-022-04134-7 · Cited by 1 · see citing works
Alam, P., Sharma, P. K., & Arshad, M. F. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202402052 · Cited by 1 · see citing works
Jin, J., & Huang, Y. (2025) · International Journal of Imaging Systems and Technology · doi:10.1002/ima.70117
Hesham, S. A., Shahin, M. I., Ziko, L., Serya, R. A. T., Farag, N. A., Abouzid, K. A. M., & Mowafy, S. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2642673
Synthesis and Evaluation of Novel Piperazine Hybrids as Promising Anticancer Agents
Daund, V., Agarwal, P., Jain, A. K., Singh, P., & Hebale, A. (2026) · Asian Journal of Chemistry · doi:10.14233/ajchem.2026.36213
Soumya, V. S., Suveena, S., Baby, J., Panicker, S. P., Laladhas, K. P., R., S. P., & Oommen, O. V. (2026) · Proceedings of the National Academy of Sciences India Section B Biological Sciences · doi:10.1007/s40011-026-01808-x
Cui, Y., Qiao, Y., Ren, H., & Qiu, L. (2026) · Pharmaceuticals · doi:10.3390/ph19091453
BindingDB (2023) · UC San Diego · doi:10.7270/q2w95f6r
Tanti, S., Gangwar, A., & Jaitak, V. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70374
- Authors
- Kumar, N., Gulati, H. K., Sharma, A., Heer, S., Jassal, A. K., Arora, L., Kaur, S., Singh, A., Bhagat, K., Kaur, A., Singh, H., Singh, J. V., & Bedi, P. M. S.
- Affiliations
- Guru Nanak Dev University (IN)
- Corresponding author
- Singh, Harbinder
- Singh, Jatinder Vir
- Bedi, Preet Mohinder Singh
- ORCID
- Venue
- Molecular Diversity
- Published
- 2020-09-04
- Volume
- 25
- Issue
- 1
- Pages
- 603-624
- ISSN
- 1381-1991 (ISSN-L)
- 1573-501X
- OpenAlex
- W3083275704
- Cited by
- 37
- References
- 60
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 5 · 2023: 7 · 2022: 9 · 2021: 3
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Diversity (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Advanced Breast Cancer Therapies
- Keywords
- breast cancer, estrogen receptor alpha, selective estrogen receptor modulators, selective estrogen receptor degrader, estrogen signaling pathway, mammary gland development, targeted cancer therapy
- MeSH terms
- Breast Neoplasms, Female, Heterocyclic Compounds, Humans, Models, Molecular, Estrogen Receptor alpha, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
